Ceftolozane/Tazobactam for the Treatment of Adults With Cystic Fibrosis: Results From a French Prospective Cohort Study.
carbapenem
cystic fibrosis
gram-negative bacteria
multidrug resistance
real-world evidence
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
received:
18
04
2024
medline:
7
8
2024
pubmed:
7
8
2024
entrez:
7
8
2024
Statut:
epublish
Résumé
People with cystic fibrosis (pwCF) are particularly susceptible to respiratory infections, including those caused by multidrug-resistant (MDR) pathogens. Ceftolozane/tazobactam (C/T) is an antibacterial agent combination active against MDR gram-negative bacteria that has shown promising results in isolates from pwCF. This subanalysis is the first extensive observation of real-world C/T use in pwCF. The multicenter observational CONDUCT study included consecutive patients, some with cystic fibrosis, who received ≥1 dose of C/T at 28 centers throughout France. Patients were treated according to hospital standards and followed up until the end of C/T treatment (EOT). Among 260 patients who had received ≥1 dose of C/T, 63 were pwCF, including 12 with previous lung transplant. The median age was 34 years and 55.6% of patients were female. C/T treatment was well tolerated and effective in pwCF, including those with previous β-lactam hypersensitivity.
Sections du résumé
Background
UNASSIGNED
People with cystic fibrosis (pwCF) are particularly susceptible to respiratory infections, including those caused by multidrug-resistant (MDR) pathogens. Ceftolozane/tazobactam (C/T) is an antibacterial agent combination active against MDR gram-negative bacteria that has shown promising results in isolates from pwCF. This subanalysis is the first extensive observation of real-world C/T use in pwCF.
Methods
UNASSIGNED
The multicenter observational CONDUCT study included consecutive patients, some with cystic fibrosis, who received ≥1 dose of C/T at 28 centers throughout France. Patients were treated according to hospital standards and followed up until the end of C/T treatment (EOT).
Results
UNASSIGNED
Among 260 patients who had received ≥1 dose of C/T, 63 were pwCF, including 12 with previous lung transplant. The median age was 34 years and 55.6% of patients were female.
Conclusions
UNASSIGNED
C/T treatment was well tolerated and effective in pwCF, including those with previous β-lactam hypersensitivity.
Identifiants
pubmed: 39108933
doi: 10.1093/ofid/ofae391
pii: ofae391
pmc: PMC11303002
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofae391Informations de copyright
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. P.-R. B. has received grants (paid to institution) from GSK and Vertex Pharmaceuticals, as well as honoraria for advisory boards/lectures from AstraZeneca, Chiesi, GSK, Insmed, MSD, Vertex Pharmaceuticals, Viatris, and Zambon. X. B. is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, New Jersey, USA. All other authors report no potential conflicts.